Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Apr 22
Central Pharmaceuticals Ltd. to Report Q3, 2026 Results on Apr 29, 2026 Central Pharmaceuticals Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026 공시 • Jan 25
Central Pharmaceuticals Ltd. to Report Q2, 2026 Results on Jan 28, 2026 Central Pharmaceuticals Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026 공시 • Nov 10
Central Pharmaceuticals Ltd. to Report Q1, 2026 Results on Nov 12, 2025 Central Pharmaceuticals Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025 공시 • Nov 05
Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025 Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttam sultan mahmud road, gulshan-02, dhaka-1212., Bangladesh 공시 • Oct 22
Central Pharmaceuticals Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025 Central Pharmaceuticals Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025 공시 • Apr 21
Central Pharmaceuticals Ltd. to Report Q3, 2025 Results on Apr 29, 2025 Central Pharmaceuticals Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025 공시 • Jan 23
Central Pharmaceuticals Ltd. to Report Q2, 2025 Results on Jan 29, 2025 Central Pharmaceuticals Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025 공시 • Nov 09
Central Pharmaceuticals Ltd. to Report Q1, 2025 Results on Nov 14, 2024 Central Pharmaceuticals Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024 공시 • Nov 05
Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024 Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2024, at 11:30 Central Asia Standard Time. Location: hall patio, gulshan club limited, house: nwj/2/a, bir uttom sultan mahmud road, gulshan 02, dhaka-1212, Bangladesh 공시 • Oct 23
Central Pharmaceuticals Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024 Central Pharmaceuticals Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024 New Risk • Oct 02
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ৳1.17b (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m (৳112m revenue, or US$931k). Market cap is less than US$10m (৳1.17b market cap, or US$9.78m). Reported Earnings • May 22
Third quarter 2024 earnings released Third quarter 2024 results: ৳0.16 loss per share. Net loss: ৳19.6m (flat on 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. 공시 • Apr 28
Central Pharmaceuticals Ltd. to Report Q3, 2024 Results on Apr 30, 2024 Central Pharmaceuticals Ltd. announced that they will report Q3, 2024 results on Apr 30, 2024 Reported Earnings • Mar 12
Second quarter 2024 earnings released: ৳0.09 loss per share (vs ৳0.08 loss in 2Q 2023) Second quarter 2024 results: ৳0.09 loss per share (further deteriorated from ৳0.08 loss in 2Q 2023). Net loss: ৳11.3m (loss widened 25% from 2Q 2023). 공시 • Jan 26
Central Pharmaceuticals Ltd. to Report Q2, 2024 Results on Jan 31, 2024 Central Pharmaceuticals Ltd. announced that they will report Q2, 2024 results on Jan 31, 2024 Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Mohammad Motaleb was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 공시 • Nov 07
Central Pharmaceuticals Ltd. to Report Q1, 2024 Results on Nov 09, 2023 Central Pharmaceuticals Ltd. announced that they will report Q1, 2024 results on Nov 09, 2023 공시 • Nov 06
Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023 Central Pharmaceuticals Ltd., Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time. Agenda: To consider No dividend for the year ended June 30, 2023. 공시 • Oct 24
Central Pharmaceuticals Ltd. to Report Fiscal Year 2023 Results on Oct 29, 2023 Central Pharmaceuticals Ltd. announced that they will report fiscal year 2023 results on Oct 29, 2023 New Risk • Jul 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$233k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (৳1.58b market cap, or US$14.6m). New Risk • Jul 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (৳25m revenue, or US$232k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (৳1.41b market cap, or US$13.0m). Reported Earnings • Jan 15
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: ৳0.072 loss per share (up from ৳9.24 loss in FY 2020). Revenue: ৳148.2m (up 5.8% from FY 2020). Net loss: ৳8.60m (loss narrowed 99% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 04
New 90-day high: ৳13.60 The company is up 11% from its price of ৳12.20 on 06 October 2020. The Bangladeshi market is up 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 18% over the same period. Reported Earnings • Dec 30
Full year 2020 earnings released: ৳9.24 loss per share The company reported a poor full year result with weaker earnings, revenues and control over expenses. Full year 2020 results: Revenue: ৳140.1m (down 54% from FY 2019). Net loss: ৳1.11b (down ৳1.16b from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 121% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 19
New 90-day high: ৳13.30 The company is up 1.0% from its price of ৳13.20 on 20 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. 공시 • Nov 06
Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020 Central Pharmaceuticals Ltd., Annual General Meeting, Dec 30, 2020, at 11:30 Bangladesh Standard Time.